Clinical Trial Design: Statistical Options/Challenges Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Deborah Collyar: What's In It for Patients?

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Varsha Gandhi, PhD, on Ibrutinib

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Lymphoma

The ASCO Post Staff

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Sep

Today In Oncology

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Related Videos

Deborah Collyar: What's In It for Patients?

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Varsha Gandhi, PhD, on Ibrutinib

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

FDA Approves Belzutifan in Combination With Lenvatinib for Advanced ccRCC

FDA Advisory Committee Votes In Favor of Approval of Multi-Cancer Early Detection Test

New AI Model Outperforms Oncotype DX for Predicting Recurrence Risk in Breast Cancer

CAP Updates Cancer Protocols for Breast Cancer Biomarker Reporting and GIST Molecular Testing

Robert Kyle Myeloma Expert Dies at 98